ARTHEx Biotech

📍 Paterna, Spain🗓 Founded 2019👥 30 employees💰 Last funded Sep 2025
Biotechnology Research🌐 arthexbiotech.com
Website LinkedIn
ARTHEx Biotech is a spin-off biotech company from the University of Valencia (Spain) focused on the research and development of novel oligonucleotide therapies that modulate microRNA to treat diseases with unmet medical needs. ARTHEx has developed its proprietary platform that allows fast and flexible development of investigational miR-modulating oligonucleotides that are designed to enter relevant tissues in pharmacological quantities, in order to treat diseases in which microRNAs play a key role. The first investigational product from this platform is ATX-01, an antimiR in development for Myotonic Dystrophy Type 1 (DM1). DM1 is an orphan disease affecting more than 900,000 people worldwide (estimated prevalence 1/8,000) with no cure, nor approved treatment to date. ATX-01 is a first-in-class disease-modifying therapy that addresses the cause of DM1 with a dual and unique mechanism of action, which targets micro-RNA-23b a key factor in the disease pathogenesis. To learn more about Arthex Biotech, please visit us at www.arthexbiotech.com
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in ARTHEx Biotech?
ARTHEx Biotech has 1 investors on record on gritt.io and 1 late-stage investors.
When did ARTHEx Biotech last raise funding?
The most recent investment in ARTHEx Biotech recorded on gritt.io was in September 2025.
When was ARTHEx Biotech founded?
ARTHEx Biotech was founded in 2019.
What industry is ARTHEx Biotech in?
ARTHEx Biotech operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is ARTHEx Biotech based?
ARTHEx Biotech is headquartered in Paterna, Spain.